KR100978592B1 - 안정한 미세 분말 칸데사탄 실렉세틸 및 이것의 제조 방법 - Google Patents

안정한 미세 분말 칸데사탄 실렉세틸 및 이것의 제조 방법 Download PDF

Info

Publication number
KR100978592B1
KR100978592B1 KR1020077002950A KR20077002950A KR100978592B1 KR 100978592 B1 KR100978592 B1 KR 100978592B1 KR 1020077002950 A KR1020077002950 A KR 1020077002950A KR 20077002950 A KR20077002950 A KR 20077002950A KR 100978592 B1 KR100978592 B1 KR 100978592B1
Authority
KR
South Korea
Prior art keywords
candesartan cilexetil
candesartan
type
desethyl
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077002950A
Other languages
English (en)
Korean (ko)
Other versions
KR20070062500A (ko
Inventor
지브 쿠간
마이클 페사쇼비치
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100978592(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20070062500A publication Critical patent/KR20070062500A/ko
Application granted granted Critical
Publication of KR100978592B1 publication Critical patent/KR100978592B1/ko
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020077002950A 2005-05-10 2006-05-10 안정한 미세 분말 칸데사탄 실렉세틸 및 이것의 제조 방법 Ceased KR100978592B1 (ko)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US67995205P 2005-05-10 2005-05-10
US60/679,952 2005-05-10
US68011505P 2005-05-11 2005-05-11
US60/680,115 2005-05-11
US68445505P 2005-05-24 2005-05-24
US60/684,455 2005-05-24
US70741705P 2005-08-10 2005-08-10
US60/707,417 2005-08-10
US70995405P 2005-08-19 2005-08-19
US60/709,954 2005-08-19
US71699505P 2005-09-13 2005-09-13
US60/716,995 2005-09-13
US72238805P 2005-09-29 2005-09-29
US60/722,388 2005-09-29

Publications (2)

Publication Number Publication Date
KR20070062500A KR20070062500A (ko) 2007-06-15
KR100978592B1 true KR100978592B1 (ko) 2010-08-27

Family

ID=37101528

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077002950A Ceased KR100978592B1 (ko) 2005-05-10 2006-05-10 안정한 미세 분말 칸데사탄 실렉세틸 및 이것의 제조 방법

Country Status (10)

Country Link
US (1) US20070082055A1 (enExample)
EP (2) EP2210888B1 (enExample)
JP (2) JP2008505935A (enExample)
KR (1) KR100978592B1 (enExample)
CA (1) CA2599415C (enExample)
DE (1) DE202006020979U1 (enExample)
ES (1) ES2429941T3 (enExample)
IL (1) IL185106A0 (enExample)
TW (1) TW200716615A (enExample)
WO (1) WO2006122254A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122254A2 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Stable micronized candesartan cilexetil and methods for preparing thereof
JP5595820B2 (ja) * 2010-01-15 2014-09-24 株式会社トクヤマ カンデサルタンシレキセチルの製造方法
WO2011109579A1 (en) 2010-03-04 2011-09-09 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof
WO2013041944A1 (en) 2011-09-19 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of micronized candesartan cilexetil
JP5930686B2 (ja) * 2011-12-07 2016-06-08 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
JP6007096B2 (ja) * 2011-12-28 2016-10-12 エルメッド エーザイ株式会社 安定化カンデサルタンシレキセチル含有物の製造方法
MX2014013320A (es) 2012-05-07 2015-08-10 Bayer Pharma AG Procedimiento de fabricacion de una forma de dosificacion farmaceutica que comprende nifedipina y candesartan cilexetilo.
EP2952187A4 (en) 2013-01-30 2016-08-17 Sawai Seiyaku Kk PHARMACEUTICAL COMPOSITION WITH CANDESARTAN CILEXETIL
JP2016106139A (ja) * 2016-03-07 2016-06-16 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US6004989A (en) * 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
DE4023369A1 (de) * 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
TW284688B (enExample) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
PT668272E (pt) * 1994-01-28 2000-10-31 Takeda Chemical Industries Ltd Processo para a producao de compostos de tetrazolilo
JP2730501B2 (ja) 1994-01-28 1998-03-25 武田薬品工業株式会社 テトラゾリル化合物の製造法
JP3003030B2 (ja) * 1997-05-26 2000-01-24 武田薬品工業株式会社 アミノベンゼン化合物の製造法
SE9901667D0 (sv) * 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
CN1204125C (zh) * 2000-12-27 2005-06-01 中国科学院上海药物研究所 坎地沙坦酯的合成新路线
CA2453890A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Crystal and process for producing the same
CA2562597A1 (en) * 2004-05-05 2005-11-24 Marina Yu Etinger Preparation of candesartan cilexetil in high purity
WO2005123720A1 (en) * 2004-06-18 2005-12-29 Ranbaxy Laboratories Limited Fine particles of the angiotensin ii antagonist candesartan cilexetil and process for production thereof
AU2006204083A1 (en) 2005-01-06 2006-07-13 Elan Pharma International Ltd. Nanoparticulate candesartan formulations
WO2006122254A2 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Stable micronized candesartan cilexetil and methods for preparing thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ROTE LISTEⓇ GMBH, ROTE LISTEⓇ 2004, entries 17154(AtacandⓇ Tabletten) and 17155(BlopressⓇ Tabletten)*
US-A-5196444, 23 March 1993*

Also Published As

Publication number Publication date
TW200716615A (en) 2007-05-01
US20070082055A1 (en) 2007-04-12
CA2599415A1 (en) 2006-11-16
JP2008505935A (ja) 2008-02-28
IL185106A0 (en) 2007-12-03
WO2006122254A2 (en) 2006-11-16
EP1763525A2 (en) 2007-03-21
EP2210888B1 (en) 2013-04-24
WO2006122254A3 (en) 2007-01-25
ES2429941T3 (es) 2013-11-18
DE202006020979U1 (de) 2011-08-05
EP2210888A3 (en) 2010-09-15
KR20070062500A (ko) 2007-06-15
JP2010270148A (ja) 2010-12-02
CA2599415C (en) 2011-07-19
EP2210888A2 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
JP2010270148A (ja) 超微粉砕された安定性カンデサルタンシレキセチル及びその調製方法
WO2013184698A1 (en) Solid forms of an antiviral compound
US20100121072A1 (en) Candesartan cilexetil polymorphs
KR20140066705A (ko) 약제 제제에 사용하기 위해 특정한 입자 크기 분포 범위와 비표면적 범위를 갖는 ｎ-[5-(아미노설포닐)-4-메틸-1,3-티아졸-2-일]-ｎ-메틸-2-[4-(2-피리디닐)페닐]아세트아미드 메실레이트 일수화물
JP2002518495A (ja) イルベサルタンの新規なフォーム、それを得る方法およびそれを含む医薬組成物
TWI848241B (zh) １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶之製備方法及包含彼之醫藥組成物
KR20160028489A (ko) 다형체 형태 ｓｔ―２４６ 및 제조방법
CN1155594C (zh) 作为抗偏头痛的药物的多晶形物的盐
TWI607006B (zh) 細胞凋亡蛋白抑制劑之固體口服調配物及晶型
CN105418614A (zh) 替格瑞洛的新结晶形式及其制备方法和用途
MX2007000523A (en) Stable micronized candesartan cilexetil and methods for preparing thereof
US20090304797A1 (en) Process for the Preparation of Micronized Valsartan
CN101171246A (zh) 稳定的微粉化坎地沙坦西酯及其制备方法
JP2005330277A (ja) カンデサルタンシレキセチル多形体
HK1196017A (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A302 Request for accelerated examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0204

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

St.27 status event code: A-5-5-V10-V13-apl-PJ0501

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20110422

Effective date: 20130227

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20110623

Effective date: 20130227

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20130227

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0978592

Appeal request date: 20110623

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2011100001456

Decision date: 20130227

Appeal event data comment text: Appeal Kind Category : Invalidation, Appeal Ground Text : 0978592

Appeal request date: 20110422

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2011100000923

EXTG Ip right invalidated
PC2102 Extinguishment

St.27 status event code: N-4-6-H10-H13-oth-PC2102

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000